BIIB logo

BIOGEN INC

BIIBNASDAQ
๐Ÿ† #333 by market capEarnings Feb 5๐ŸงฌBiotech
$249.59โ–ฒ $2.47 (+1.00%)
Market closed ยท at close
๐Ÿ””
Track BIIB
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ฒ 1.0%
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$36.89B
Mid Cap
๐Ÿ“ˆRevenue Growth (YoY)
2.3%
Slowing
๐Ÿ“ŠGross Margin
74.0%
High
๐Ÿ’ตFCF Margin
16.5%
Healthy
โš–๏ธP/S Ratio
3.6x
Fair
Otter Score
76
Strong
No chart data available for BIIB.

Trading Snapshot

Day Range
$248.04 โ€“ $252.77
52-Week Range
$160.36 โ€“ $261.00
Volume (shares)
1,132,508
Avg Volume (shares)
โ€”
Shares Outstanding
147.8M
Next Earnings
2027-02-05

Fundamentals Snapshot

Annual Revenue
$9.81B
Last Q Revenue
$2.80B
P/E Ratio
106.9
P/S Ratio
3.6x
EPS (TTM)
$2.34
Dividend Yield
โ€”
Dilution (1yr)
+0.4%
BIIB logo

BIOGEN INC

BIIB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$9.8Bโ–ฒ +1.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
70.5%โ–ผ โˆ’7.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
$1.9Bโ–ผ โˆ’24.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$2.1Bโ–ผ โˆ’18.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
146.7Mโ–ฒ +0.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
โˆ’$3.9Bโ–ฒ +$316M YoY
StockOtter ยท stockotter.space

About BIOGEN INC

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Strong
76/100
Analyst data unavailable.

Latest News & Updates

Seeking Alphaยท2d ago

Biogen: Why I'm Still Bullish Despite Market Turmoil

Biogen Inc. shares remain in an uptrend despite broader market pressure from the selloff in AI-related stocks. Its "star," called Leqembi, generated $202 million in Q3 global in-market sales, up 9.8% quarter-over-quarter

Seeking Alphaยท3d ago

Biogen: M&A Growth And Alzheimer's Progress Are Now Priced In (Rating Downgrade)

Biogen Inc. moves from Buy to Hold: after a 20% gain, its valuation reasonably reflects growth and marginally positive Alzheimer's developments. BIIB trades above my July $223.70 DCF estimate; raising assumed growth from

PRNewsWireยท3d ago

Clarity AD CSF Substudy Findings on Lecanemab Treatment and ฮฑ-Synuclein Co-Pathology Presented at CTAD 2026

Lecanemab showed favorable results on clinical assessment scores at 18 months, including among individuals with early Alzheimer's disease (AD) who were ฮฑ-synuclein positive, a subgroup associated with higher amyloid burd

Defense Worldยท3d ago

Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019

Biogen (NASDAQ: BIIB) expects to announce results from two systemic lupus erythematosus trials together in a press release, as the company prepares for a series of pipeline readouts and seeks to return to revenue growth,

Defense Worldยท3d ago

Biogen Inc. $BIIB Shares Bought by Bogart Wealth LLC

Bogart Wealth LLC increased its position in shares of Biogen Inc. (NASDAQ: BIIB) by 1,367.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. T

PRNewsWireยท4d ago

New Three-Year Real-World LEQEMBIยฎ Data Presented at CTAD 2026

Largest analysis of LEQEMBI LEADER study reported to date includes findings on amyloid clearance in routine clinical practice, delayed progression to moderate or severe AD, expanded subcutaneous maintenance experience, a